CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be avail ...

LONDON, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced participation in a series of industry conferences and trade programs in March and April 2026. These events provide multiple platforms to engage stakeholders across ...

Core Insights - PMV Pharmaceuticals announced the publication of Phase 1 results for rezatapopt in the New England Journal of Medicine, demonstrating its potential in treating advanced solid tumors with a TP53 Y220C mutation [1][2][4] Group 1: Study Results - The Phase 1 portion of the PYNNACLE clinical trial involved 77 heavily pretreated patients, focusing on safety, pharmacokinetics, and determining the maximum tolerated dose of rezatapopt [3][6] - Objective responses were observed across multiple tumor types, with clinical activity linked to selective binding to the Y220C pocket and restoration of wild-type p53 function [3] - The overall response rate (ORR) across all cohorts was 34% (35 out of 103 patients), with a 46% ORR (22 out of 48 patients) specifically in ovarian cancer [4] Group 2: Drug Information - Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate p53 by selectively binding to the p53 Y220C mutant protein [5] - The FDA has granted Fast Track designation to rezatapopt for treating locally advanced or metastatic solid tumors with a p53 Y220C mutation [5] Group 3: Future Plans - The company plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027 [4] - The ongoing Phase 2 portion of the PYNNACLE trial aims to evaluate the efficacy of rezatapopt in various solid tumors with TP53 Y220C and KRAS wild-type mutations [6]

Fourth Quarter Revenue of $683 million, down 0.4% Year-over-Year; 2025 Revenue of $2,686 million, down 2% Year-over-YearFourth Quarter Private Cloud Revenue of $241 million, down 10% Year-over-Year; 2025 Private Cloud Revenue of $990 million, down 6% Year-over-YearFourth Quarter Public Cloud Revenue of $442 million, up 6% Year-over-Year; 2025 Public Cloud Revenue of $1,696 million up 1% Year-over-YearFourth Quarter Cash Flow From Operating Activities of $60 million; 2025 Cash Flow From Operating Activities ...

Core Insights - The company has reported results from a targeted historic core resampling program at its 100%-owned Jean Lake Gold-Lithium Property, aimed at improving the understanding of gold distribution along the Valkyrie and Midas Gold Trends [1][2] Summary of Results - The resampling program identified additional mineralized sections and improved the representation of gold distribution within the Valkyrie structural corridor, supporting the refinement of geological interpretation [2][3] - The integration of new assay results from the 2025 gap-fill resampling program with previously reported gold intercepts from the 2023 drill program shows that mineralization extends beyond earlier reported intercepts [3][6] Significant Assay Results - Notable assay results include: - FM23-25: 1.10 g/t Au over 8.0 metres from 22.0–30.0m, including 6.9 g/t Au over 0.5 metres [5] - FM23-08: 0.64 g/t Au over 10 metres from 106.5-116.9m [5] - The updated interpretation indicates that the Valkyrie Trend has been traced over approximately 600 metres of strike length [9] Next Steps - The company plans to integrate the new gap-fill assay results with the 2025 drill program results to assist in the next phase of exploration, which will include step-out and infill drilling aimed at expanding the mineralized footprint [9][15] Quality Control and Analytical Methods - All drill core samples were collected as NQ-sized core, with systematic sampling conducted in mineralized zones and continuous sampling outside these zones [10] - Samples were analyzed by SGS Canada Inc., utilizing methods such as Fire Assay and multi-element geochemical analyses, ensuring strict quality control protocols [10][11]

Transaction expands Mixie’s platform strategy into immersive real estate visualization and technology-enabled property management DENVER, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mixie Technologies, Inc. (OTC: PHCG), formerly known as Pure Harvest Corporate Group, Inc. (“Mixie” or the “Company”) today announced that it has closed on the acquisition of a 25 percent minority ownership interest in Mixie Realty, LLC (“Mixie Realty”), a next-generation real estate visualization and property management platform. The tra ...

VANCOUVER, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discoveries, is pleased to announce the successful completion and expiry of its Warrant Acceleration Program (the “Acceleration”) of outstanding common share purchase Warrants of the Company issued in connection with a financing that closed in two tranches on May 23 and July 31, 2025 (the “May Finan ...

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company found ...

MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,600,000 sq. ft., is pleased to announce that it has received final approval to graduate (the "Uplisting") from the TSX Venture Exchange to the Toronto Stock Exchange (the "TSX"). "Graduating to the TSX represents a sign ...

Park brings over 20 years of industry experience to expand innovation and drive brand partner growth ROMEOVILLE, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoolie Park as Vice President of Brand Partnerships. In this role, Park will lead strategic relationships with emerging and established beauty brands, expanding Solésence’s ability to delive ...